Brian Gormley

1 week ago | wsj.com | Brian Gormley

June 18, 2025 9:15 pm ET|WSJ ProCancer-testing company Caris Life Sciences surged in its stock-market debut Wednesday, continuing a run of strong initial public offerings for revenue-making healthcare companies. Shares of the Irving, Texas-based company rose more than 33.3% from their IPO price of $21 a share, closing at $28 a share. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Exclusive venture capital news and commentary.

2 weeks ago | wsj.com | Brian Gormley

Startup says its artificial-intelligence agent can make autonomous calls to patientsWhen hospitals discharge patients, finding enough caregivers to follow up with them can be difficult. Ellipsis Health wants to fill those gaps using artificial intelligence. The San Francisco-based health-technology company has raised $45 million in new venture capital to expand the use of its AI-driven software that can make or receive phone calls autonomously to check in on patients between doctor visits.

2 weeks ago | createsend.com | Brian Gormley

Good day. The Damon Runyon Cancer Research Foundation each year gives about $20 million in grants to scientists. Now it plans to give them venture capital, too. The New York-based foundation, which funds high-risk, high-reward science, has created a seed-investment program for researchers who have received its grants since 2000 and have now launched companies.

2 weeks ago | createsend.com | Brian Gormley

Good day. Now might not seem like the ideal time for startups to go public, but then again maybe that’s changing. Crypto firm Circle shot up in its stock-market debut Thursday, while adtech MNTN and digital-health platform Hinge Health staged strong IPOs in late May. So for this week’s question, we want to know what attributes you think make a company a strong candidate to go public in today’s market. Email responses to [email protected].

4 weeks ago | wsj.com | Brian Gormley

Western drugmakers, investors increasingly aim to acquire Chinese compoundsMay 29, 2025 6:00 am ET|WSJ ProU.S. venture capitalists are racing to tap in to China’s growing biotechnology prowess, a shift moving the industry into a more global market for the most promising new drug candidates. Several licensing pacts between Western and Chinese drugmakers have marked China’s emergence in biotech, a rise decades in the making.